DR10627 / Huadong Medicine, Heze Pharma - LARVOL DELTA

Huadong Medicine: Doerr Biopharma's triple agonist DR10627 completes Phase 1 clinical trial [Google translation] (163.com) - "The product under development DR10627 of the company's holding subsidiary Doer Bio is a triple agonist targeting GLP-1R/GIPR/GCGR, and has completed Phase 1 clinical trials. In addition, Doer Bio's FGF21R/GCGR/GLP-1R triple-target agonist DR10624 is currently conducting a Phase II clinical study for the treatment of metabolic-related fatty liver disease with a high risk of liver fibrosis and metabolic-related alcohol-related fatty liver disease, and the first subject will be enrolled in April 2025. At the same time, another Phase II clinical study of DR10624 for the treatment of severe hypertriglyceridemia, which has been launched, has completed the enrollment of all patients."

Trial completion • Trial status • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Severe Hypertriglyceridemia

DR10627, a Novel Dual Glucagon‑like Peptide‑1 and Gastric Inhibitory Polypeptide Receptor Agonist for the Treatment of Obesity and Type 2 Diabetes Mellitus. (PubMed, Diabetes Metab Syndr Obes) - "Moreover, DR10627 had a potent glucose-lowering effect in db/db mice, and the hypoglycemic effect of 18 nmol/kg DR10627 was better than that of 50 nmol/kg liraglutide. Preclinical assessment demonstrated that administration of DR10627 resulted in glucose lowering in SD rats and db/db mice, and substantial body weight reduction and metabolism improvement in DIO mice. DR10627 is a promising agent deserving further investigation for the treatment of type 2 diabetes and obesity."

Journal • Diabetes • Genetic Disorders • Inflammation • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus